Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH）

Xi'an Jiaotong University

Status: Enrolling

Conditions: Cardiomyopathies

Treatments: Biological: Diagnosis of NDLVC; Biological: Diagnosis of RCM; Biological: Diagnosis of LVNC; Biological: Diagnosis of DCM; Biological: Diagnosis of ARVC; Biological: Diagnosis of HCM

Study type: Observational

Funder types: Other

Identifiers

NCT06352320

XJTU1AF2023LSK-533

Details and patient eligibility

About

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Full description

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >18 years old.
• The diagnosis of cardiomyopathy was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
• Patients or their families agreed to participate in the study and authorized informed consent.

Exclusion criteria

• Incomplete clinical data.
• Do not agree to the inclusion or refuse to authorize the informed consent.

Trial design

500 participants in 6 patient groups

HCM group

Description:

Patients were diagnosed with HCM.

Treatment:

Biological: Diagnosis of HCM

DCM group

Description:

Patients were diagnosed with DCM.

Treatment:

Biological: Diagnosis of DCM

ARVC group

Description:

Patients were diagnosed with ARVC.

Treatment:

Biological: Diagnosis of ARVC

NDLVC group

Description:

Patients were diagnosed with NDLVC.

Treatment:

Biological: Diagnosis of NDLVC

RCM group

Description:

Patients were diagnosed with RCM.

Treatment:

Biological: Diagnosis of RCM

LVNC group

Description:

Patients were diagnosed with LNVC.

Treatment:

Biological: Diagnosis of LVNC